





MIRRORS Study


- **Robotic IDS is feasible for advanced ovarian cancer**
- **1 year morbidity and mortality is reassuringly safe**
- **Reduced demands on intensive care**
- **MIRRORS reduced time to chemotherapy**




Method

- Single site prospective cohort feasibility study of robotic IDS
 - Royal Surrey NHS Foundation Trust Guildford
 - June 26th 2020 - 21st May 2021
- Stage IIIc-IVb Epithelial ovarian cancer
- Neo-adjuvant chemotherapy + suitable for IDS
- Pelvic mass $\leq 8\text{cm}$

Primary Outcome – Feasibility of Recruitment



MIRRORS protocol –
Robot-assisted laparoscopic assessment proceeding to robotic or open IDS




Results

- **95.8%** accepted inclusion in MIRRORS
- 20 Robotic (87.0%), 3 Open (13%)
 - All High grade serous,
 - All BRCA negative,
 - no complete responders
 - 56.5% Stage 4
 - Median PCI - 24 (6-38)

Robotic Outcomes:


- **1.5 days** Median Length of stay (1-17)
- **50ml** Median EBL (20-500)
- **18.5 days** to chemotherapy (13-28)
 - Historical 28 days (21-59)
 - Open NOT MIRRORS 35 (21-64)

Quality of Life



Symptom scores for **nausea** ($p=0.032$) and **pain** ($p=0.030$) were significantly lower in MIRRORS Robot vs MIRRORS Open.

1yr Overall Survival



MIRRORS n = 21
1Y survival = 90.4% (95% CI = 77.9, 100%)

OPEN and NOT MIRRORS n = 11
1Y survival = 72.7% (95% CI = 46.4, 99.0%)

Historical Cohort n = 37
Median = 28 months (95% CI = 20.07, NA months)
1Y survival = 83.7% (95% CI = 71.1, 96.4%)

1 yr Overall Survival: no statistically significant difference to historical cohort or non-MIRRORS cohort



CHRISTINA UWINS | HASANTHI ASSALAARACHCHI | KATE BENNETT | JAMES READ | ANIL TAILOR | JAMES CRAWSHAW
JAYANTA CHATTERJEE | PATRICIA ELLIS | SIMON SKENE | AGNIESZKA MICHAEL | SIMON BUTLER-MANUEL

